RUNX2 and neoplasm: Therefore, in tumor cells exhibiting constitutive activation of the PI3K/AKT pathway, by various mechanisms such as RAS mutation, PTEN deletion, PI3K mutation, or receptor tyrosine kinase overexpression, it is conceivable that GSK3β inactivation will prevent the repression of RUNX2 transcriptional activity.